AcquisitionOther
RayzeBio, Inc. acquired RayzeBio
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
RayzeBio, Inc. -> RayzeBio · $62.50
RayzeBio is a clinical-stage radiopharmaceutical therapeutics (RPT) company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs.
Open source record (SEC) ↗